Soleno-sponsored manuscripts – Content provided on this page are intended for scientific exchange and may include references to or data/information regarding a Soleno investigational product or use of a Soleno product that has not been FDA approved; no conclusions regarding the safety or efficacy can be made. Furthermore, this information should not be construed as recommendation for use of, or intent to promote a Soleno product for unapproved uses.
2024 – Study C610 (C601/C602-Open Label Extension Comparison for PATH for PWS)
Behavioral changes in patients with Prader-Willi syndrome receiving diazoxide choline extended-release tablets compared to the PATH for PWS natural history study.
2024 – Study C601/C602-Open Label Extension
Diazoxide choline extended-release tablet in people with Prader-Willi syndrome: results from long-term open-label study.
2023 – Study C601
Diazoxide choline extended-release tablet in people with Prader-Willi syndrome: a double-blind, placebo-controlled trial.
2021 – Study CASIMIR (sub-study for C601/C602-Open Label Extension)
A qualitative methodology to support the evaluation of novel treatments for hyperphagia in people with Prader-Willi syndrome.
2020 – Review: ATP-Sensitive Potassium Channel Activation
The potential role of activating the ATP-sensitive potassium channel in the treatment of hyperphagic obesity.
2019 – PC025 Phase 2 Proof of Concept
A randomized pilot efficacy and safety trial of diazoxide choline controlled-release in patients with Prader-Willi syndrome.
You are now leaving Soleno Medical
The link you are selecting will direct you to an external website maintained by third parties that are neither owned, endorsed, nor controlled by Soleno. The link is provided for your convenience and informational purposes only.
Soleno does not endorse or control the content, privacy policies, or terms of use/services on external sites. Any opinions, claims, or comments expressed on external sites should not be attributed to Soleno.
